1. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies. (6th April 2017) Authors: Norris, Stephen; Ramael, Steven; Ikushima, Ippei; Haazen, Wouter; Harada, Akiko; Moschetti, Viktoria; Imazu, Susumu; Reilly, Paul A.; Lang, Benjamin; Stangier, Joachim; Glund, Stephan Journal: British journal of clinical pharmacology Issue: Volume 83:Number 8(2017) Page Start: 1815 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study. Issue 2 (5th August 2017) Authors: Yasaka, Masahiro; Ikushima, Ippei; Harada, Akiko; Imazu, Susumu; Taniguchi, Atsushi; Norris, Stephen; Gansser, Dietmar; Stangier, Joachim; Schmohl, Michael; Reilly, Paul A. Journal: Research and practice in thrombosis and haemostasis Issue: Volume 1:Issue 2(2017) Page Start: 202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗